ACI: A Focus on Community Clinicians
Monday, June 19, 2023
Live via Zoom Webinar
#LearnACI

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from Asta/eneva, Bristol Myers Squibb, Lexicon, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation. (as of 5/17/2023)
Thank You To Our Supporters

The 2023 Advances in Cancer Immunotherapy™ Comprehensive Educational Programming series is generously supported, in part, by independent medical education grants from:

PLATINUM

Bristol Myers Squibb
Merck Sharp & Dohme, Corp.,
a subsidiary of Merck & Co., Inc. (MSD)

GOLD

AstraZeneca

SILVER

Exelixis

BRONZE

Novartis Pharmaceuticals Corporation
**Target Audience**

The ACI Community Clinician program is a CME certified course geared specifically for community clinicians using cancer immunotherapy in a clinical setting.

**Learning Objectives**

Upon completion of this program, participants will be able to:

- Summarize recent updates in the use of bispecific antibodies.
- Identify PDL-1 inhibitors in the small cell lung cancer landscape.
- Describe T-cell therapies in hematological malignancies and emerging cellular therapies in solid tumors.

**Organizers**

- Sigrun Hallmeyer, MD  
  Advocate Health Care
- Raju Vaddepally, MD  
  Yuma Regional Medical Center

**Faculty**

- Natalie Callander, MD  
  University of Wisconsin, Madison
- Sandip Patel, MD  
  University of California, San Diego

**Program Agenda**

*Please note all times are in CDT.*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–1:05 p.m.</td>
<td>Welcome</td>
</tr>
</tbody>
</table>
| 1:05–1:25 p.m.     | Bispecific Antibodies in Cancer Care: Actual Reality and Future Projections  
  Sandip Patel, MD |
| 1:25–1:40 p.m.     | ES-SCLC: Changing Paradigms with Immuno-Oncotherapy Combinations  
  Sandip Patel, MD |
| 1:40–2:00 p.m.     | CAR-T Therapy for Hematologic Malignancies and Solid Tumors  
  Natalie Callander, MD |
| 2:00–2:15 p.m.     | Toxicities Associated with CAR-T Therapy  
  Natalie Callander, MD |
| 2:00–2:25 p.m.     | Question & Answer Session                                                                   |
| 2:25 p.m.          | Concluding Remarks                                                                            |

**On-demand**

Registrants will receive an email within two weeks with a link to the recorded seminar and slides (as permitted by the presenters). If you do not receive an email, please contact SITC at connectED@sitcancer.org.
Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

<table>
<thead>
<tr>
<th>Name of Faculty</th>
<th>Reported Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sigrun Hallmeyer, MD</td>
<td>Consultant Advisor Speaker: Bristol Meyers Squibb, Cardinal Health; Executive Role: ACCC IO Institute</td>
</tr>
<tr>
<td>Raju Vaddepally, MD</td>
<td>Executive Role: ACCC IO Institute, TACOS; Researcher: ACCRU; Consultant Advisor Speaker: Cancer Expert Now, Tempus; Publicly Traded Stocks: Crisper, Teladoc, Blue, KPTI, Illumina, Amwell</td>
</tr>
<tr>
<td>Natalie Callander, MD</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Sandip Patel, MD</td>
<td>Researcher: Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech, SQZ Biotechnologies, Takeda; Consultant Advisor Speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina, Merck, Pfizer, Rakuten, Tempus</td>
</tr>
</tbody>
</table>

Planners and Managers

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Biographies:

**Sigrun Hallmeyer – Advocate Health Care**

Sigrun Hallmeyer, MD was born and raised in East Berlin, Germany, and escaped to West Germany at the age of 18. Dr. Hallmeyer studied medicine at one of the oldest universities in Europe before moving to the United States for her clinical training in internal medicine. She completed her fellowship in hematology and medical oncology at the University of Illinois in 2005. Her clinical practice is focused on melanoma, immuno-oncology, and breast cancer. Today, Dr. Hallmeyer is a practicing medical oncologist and hematologist and serves as attending physician and key teaching faculty member at Advocate Lutheran General Hospital in Park Ridge, Illinois. Dr. Hallmeyer served as chair of the cancer committee for several years before becoming medical director of the ALGH Cancer Survivorship Center which she founded in 2013 as the first free-standing campus center of its kind in Illinois. She then served as Director of the Cancer Service Line at Advocate Lutheran General Hospital in 2019.

**Raju Vaddepally, MD – Yuma Regional Medical Center**

Raju Vaddepally, MD received his medical degree at Osmania Medical College, affiliated with N.T.R. University of Health Sciences in Hyderabad, India. He completed his residency in internal medicine from St. Joseph Mercy Hospital in Ann Arbor, Michigan. During his residency he developed an immense interest in taking care of cancer patients which motivated him to pursue additional training in oncology and hematology. Dr. Vaddepally completed a fellowship in hematology and oncology at Josephine Ford Cancer Institute at Henry Ford Hospital, which is affiliated with Wayne State University in Detroit, MI. Dr. Vaddepally is a member of the American Society of Hematology and American Society of Clinical Oncology. He is also a member of the American College of Physicians.
Natalie Callander, MD – University of Wisconsin, Madison
Natalie Callander, MD is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine. She is the Director of the UW Carbone Cancer Center Myeloma Clinical Program, Vice Chair of the NCCN Myeloma Committee, and Interim Director of Bone Marrow Transplant. She is a member of the NCI Myeloma Steering Committee and the ECOG Myeloma Committee. She has received three UW Health Patient Experience Physician Champion Awards, named to Best Doctors in America list since 2004, a Madison Magazine Top Doctor three times, and received the Chuck Koval Award for Excellence in Myeloma presented by the Leukemia and Lymphoma Society. Dr. Callander’s clinical focus is on multiple myeloma, malignant hematology, transplant and quality of life. Dr. Callander’s current research is focusing on new therapies in all stages of multiple myeloma and the development of clinical trials. She is the Principal Investigator on a national trial looking at early treatment for smoldering myeloma. She is also actively involved in the development of cellular therapies for multiple myeloma.

Sandip Patel, MD – University of California, San Diego
Sandip Patel, MD is a Professor at UCSD and a Medical Oncologist focusing on early-phase clinical trials of immunotherapy and thoracic oncology. He is the leader for the Experimental Therapeutics (Phase 1) Program and Deputy Director for the Center for Precision Immunotherapy at UCSD. He is Director of the Clinical Trials Office at UCSD Moores Cancer Center. He is co-leader of the NRG Developmental Therapeutics Committee and co-leader of the University of California Lung Cancer Consortium.
Advances in Cancer Immunotherapy™
Online Education Series

Continue learning after today’s program

As a component of the ACI programs, SITC is pleased to offer free online, CME-, CPE-, CNE- and MOC programs via the society’s online learning portal, SITC Cancer Immunotherapy connectED. Included in these programs are:

Online Advances in Cancer Immunotherapy™ Courses
These CME, CNE, CPE and MOC available courses utilize the live webinar content to create an online course accessible from the comfort of your own home or office and flexible to your schedule. Access these courses today to learn from experts in the field as they discuss the latest updates and go through case studies providing invaluable practical knowledge.

Foundational Concepts to Reinforce your Learning
Three interactive CME, CNE, CPE, and MOC online courses give the learner an in-depth overview of core principles of immunology and immunotherapy.

New offerings will be coming throughout 2023 – check our site frequently for updated content

Visit sitcancer.org/acionline today to view complete accreditation information for these ACI online programs.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation. (as of 5/17/2023)